has no way to protect itself if competitors overinvest in facilities and bring down industrywide pricing.WuXi relies on Merck for more than 15% of sales.With the majority of firm revenue coming from China, the firm is exposed to any negative
Alnylam Pharamaceuticals ( ALNY ) finalizes its buy of Merck 's ( MRK ) Sirna Therapeutics that was previously disclosed on ..... The transaction represents a significant haircut for Merck considering the $1.1B cash price it paid for Sirna
Merck 's ( MRK ) Q4 EBITDA of $1.1B meets consensus estimate . Annual profit will be $4.45B slightly under the consensus target of $4
FRANKFURT, March 6 (Reuters) - The chief executive of German liquid crystal maker Merck KGaA, Karl-Ludwig Kley, said he was confident the planned takeover of Britain's AZ Electronic Materials could be completed
Merck KGaA reported fourth-quarter results that largely ..... estimate or moat ratings. Over the last year, Merck has been able to rely on cost-cutting to ..... cost-cutting have largely been realized. Merck ’s fourth-quarter results capped a very
FRANKFURT, March 6 (Reuters) - Lanxess AG on Thursday said Matthias Zachert, currently Chief Financial Officer of Merck KGaA, would take over as Chief Executive of Lanxess from April 1, 2014.
* Q4 adjusted EBITDA 795 mln euros vs average forecast of 784 mln
FRANKFURT, March 6 (Reuters) - Germany's Merck KGaA , the worlds largest maker of liquid crystals for display screens, reported an unexpected slight increase in adjusted core earnings, as it continued to benefit from a cost cutting programme.
March 5 (Reuters) - A combination of oral drugs for hepatitis C developed by Merck & Co appeared to be well tolerated and highly effective in treating the liver disease in patients also infected with HIV, according to data from a midstage clinical trial presented on Wednesday.
March 4 (Reuters) - An immunotherapy pill to treat an allergy to house dust mites being tested by Merck & Co significantly reduced common nasal symptoms, such as sneezing and stuffy nose, according to data from a midstage clinical trial, the company said on Tuesday.